Technical Analysis for HTBX - Heat Biologics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 5.95 | 2.94% | 0.17 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Historical HTBX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Buy Signal | Bullish | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Below Lower BB | Weakness | 2.94% | |
| Down 3 Days in a Row | Weakness | 2.94% | |
| Lower Bollinger Band Touch | Weakness | 2.94% | |
| Oversold Stochastic | Weakness | 2.94% | |
| NR7 | Range Contraction | -1.65% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | 2 days ago |
| Up 3% | 2 days ago |
| Possible Inside Day | 2 days ago |
| Possible NR7 | 2 days ago |
| Up 2% | 2 days ago |
Free Daily (Stock) Chart Reading
- Earnings date: 09/27/2019
Heat Biologics, Inc. Description
Heat Biologics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of various cellular therapeutic vaccines for a range of cancers and infectious diseases. It is developing Immune Pan Antigen Cytotoxic therapy, a platform technology that delivers human cells that are reprogrammed to pump out various cancer associated antigens together with a potent immune adjuvant. The company's products under development include HS-110 that is in Phase II clinical trials for the treatment of non-small cell lung cancer; HS-410 for the bladder cancer treatment; HS-310 to treat ovarian cancer; and HS-510 for treating triple negative breast cancer. Its products also comprise HS-HIV product candidate for the treatment and prevention of HIV. The company was founded in 2008 and is based in Chapel Hill, North Carolina.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Infectious Diseases Treatment Of Cancer Cancers Breast Cancer Treatment Of Breast Cancer Small Cell Lung Cancer Non Small Cell Lung Cancer Ovarian Cancer Vaccine Vaccination Cancer Treatment HIV Platform Technology Bladder Cancer Treatment Of Non Small Cell Lung Cancer Cancer Vaccine Triple Negative Breast Cancer Chapel Hill Heat Biologics Neuvenge
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 30.1 |
| 52 Week Low | 4.34 |
| Average Volume | 476,203 |
| 200-Day Moving Average | 8.15 |
| 50-Day Moving Average | 7.26 |
| 20-Day Moving Average | 6.58 |
| 10-Day Moving Average | 6.36 |
| Average True Range | 0.43 |
| ADX | 20.16 |
| +DI | 11.61 |
| -DI | 27.25 |
| Chandelier Exit (Long, 3 ATRs ) | 6.10 |
| Chandelier Exit (Short, 3 ATRs ) | 6.97 |
| Upper Bollinger Band | 7.42 |
| Lower Bollinger Band | 5.74 |
| Percent B (%b) | 0.12 |
| BandWidth | 25.52 |
| MACD Line | -0.34 |
| MACD Signal Line | -0.28 |
| MACD Histogram | -0.0617 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.24 | ||||
| Resistance 3 (R3) | 6.21 | 6.10 | 6.19 | ||
| Resistance 2 (R2) | 6.10 | 6.02 | 6.11 | 6.17 | |
| Resistance 1 (R1) | 6.02 | 5.98 | 6.06 | 6.05 | 6.16 |
| Pivot Point | 5.91 | 5.91 | 5.93 | 5.92 | 5.91 |
| Support 1 (S1) | 5.83 | 5.83 | 5.87 | 5.86 | 5.74 |
| Support 2 (S2) | 5.72 | 5.79 | 5.73 | 5.73 | |
| Support 3 (S3) | 5.64 | 5.72 | 5.71 | ||
| Support 4 (S4) | 5.67 |
